Wells Fargo Downgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Negative 84.0%

Neg 84% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Overweight to Equal-Weight and raises the price target from $35 to $42.